参考文献/References:
[1] Wei L K, Au A, Menon S, et al. Clinical relevance of MTHFR, eNOS, ACE, and ApoE gene polymorphisms and serum vitamin profle among malay patients with ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2015 24(9):2017-2025.
[2] Viola J,Soehnlein O.Atherosclerosis - A matter of unresolved inflammation[J].Semin Immunol,2015,27(3):184-193.
[3] 杜晴,于晓晶,李红娟,等.类风湿关节炎患者血清前,蛋白转化酶枯草溶菌素 9 水平及其意义[J].中华内科杂志,2017,56(9):655-659.
[4] Abifadel M,Varret M,Rabès JP,et al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J].Nat Genet,2003,34(2):154-156.
[5] Bergeron N,Phan BA,Ding YC,et al.Proprotein convertase subtilisin/kexin type 9 inhibition a new therapeutic mechanism for reducing cardiovascular disease risk[J].Circulation,2015,132(17):1648-1666.
[6] Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9(PCSK9):hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration[J]. Hepatology, 2008, 48(2):646-654.
[7] Schmidt RJ,Zhang YY,Zhao Y,et al.A novel splicing variant of proprotein convertase subtilisin/kexin type 9[J].DNA Cell Biol,2008,27(4):183-189.
[8] Welder G,Zineh I,Pacanowski MA,et al.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol[J].J Lipid Res,2010,51(9):2714-2721.
[9] Bea AM, Perez-Calahorra S, Marco-Benedi V, et al. Effect of in-tensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia[J]. Atherosclerosis, 2017,263:92-96.
[10] Hopewell JC,Malik R,Valdés-Márquez E,et al.Differential ef-fects of PCSK9 variants on risk of coronary disease and ischaemic stroke[J].Eur Heart J,2018,39(5):354-359.
[11] Baass A,Dubuc G,Tremblay M,et al.Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a Population-Based sample of children and adolescents[J].Clin Chem,2009,55(9):1637-1645.
[12] Dubuc G,Tremblay M,Paré G,et al.A new method for measure-ment of total plasma PCSK9:clinical applications[J].J Lipid Res,2010,51(1):140-149.
[13] 张娜,李志勇,李林森.Ox-LDL与动脉粥样硬化的关系及中药抗氧化作用的研究进展[J].云南民族大学学报(自然科学版),2013,22(5):313-316.
[14] Libby P,Ridker PM,Hansson GK.Progress and challenges in translating the biology of atherosclerosis[J].Nature,2011,473(7347):317-325.
[15] Li J,Liang X,Wang Y,et al.Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDLinduced endothelial cell apoptosis[J].Mol Med Rep,2017,16(2):1817-1825.
[16] Iida Y,Tanaka H,Sano H,et al.Ectopic expression of PCSK9 by smooth muscle cells contributes to aortic dissection[J].Ann Vasc Surg,2018,48(6):195-203.
[17] 陈露,袁婷婷,徐将,等.前蛋白转化酶枯草溶菌素9与动脉粥样硬化及斑块破裂的关系[J].分子生物医学,2017,23(24):4785-4790.
[18] Rashid H,Meredith IT,Nasis A.PCSK9 monoclonal antibodies in 2016:current status and future challenges[J].Heart Lung and Circulation,2017,26(8):786-798.
[19] Momtazi AA,Banach M,Pirro M,et al.PCSK9 and diabetes:is there a Link?[J].Drug Discov Today,2017,22(6):883-895.
[20] Zhang DW,Lagace TA,Garuti R,et al.Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation[J].J Biol Chem,2007,282(25):18602-18612.
[21] Gouni-Berthold I.PCSK9 antibodies:A new class of lipid-lowering drugs[J].Atheroscler Suppl,2015,18:21-27.
[22] Pirro M,Bianconi V,Francisci DA,et al.Hepatitis C virus and proprotein convertase subtilisin/kexin type 9:a detrimental interaction to increase viral infectivity and disrupt lipid metabolism[J].J Cell Mol Med,2017,21(12):3150-3161.
[23] Kwon HJ,Lagace TA,Mcnutt MC,et al.Molecular basis for LDL receptor recognition by PCSK9[J].Proc Natl Acad Sci U S A,2008,105(6):1820-1825.
[24] Yamamoto T,Lu C,Ryan RO.A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor[J].J Biol Chem,2011,286(7):5464-5470.
[25] Lo Surdo P,Bottomley MJ,Calzetta A,et al.Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH[J].EMBO Rep,2011,12(12):1300-1305.
[26] Chorba JS,Galvan AM,Shokat KM.Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and Link clinical genotype to lipid phenotype[J].J Biol Chem,2018,293(6):1875-1886.
[27] 周鑫斌,武丽,毛威.LXR-IDOL-LDLR轴在脂质平衡中作用研究进展[J].浙江中医药大学学报,2014,38(9):1131-1134.
[28] Chan DG,Barrett PH.Plasma proprotein convertase subtilisin/kexintype 9:a marker of LDL apolipoprotein B[J].DOI:10.1373/clinchem,2009,55(11):2049-2052.
[29] Cui Q,Ju XX,Yang T,et al.Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population[J].Atherosclerosis,2010,213(2):632-636.
[30] Wang Y, Ye J, Li J, et al. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9(PCSK9)[J]. Cardiovasc Diabetol, 2016,15:19.
[31] Miao J,Manthena PV,Haas ME,et al.Role of insulin in the regu-lation of proprotein convertase subtilisin/kexin type 9[J].Arterioscler Thromb Vasc Biol,2015,35(7):1589-1596.
[32] Costet P,Cariou B,Lambert G,et al.Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c[J].J Biol Chem,2006,281(10):6211-6218.
[33] 张兴渝,杨媚,梁丹,等.本研究2型糖尿病患者血清前蛋白转化酶枯草溶菌素9水平的变化及其相关性研究[J].基础研究,2018,43(9):1153-1156.
[34] Yang SH,Li S,Zhang Y,et al.Positive correlation of plasma PCSK9 levels with HbA(1c)in patients with type 2 diabetes[J].Diabetes Metab Res Rev,2016,32(2):193-199.
[35] Mueller-Wieland D,Leiter LA,Cariou BA,et al.Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial:lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk[J].Cardiovasc Diabetol,2017,16(1):70.
[36] Jellinger PS,Handelsman Y,Rosenblit PD,et al.American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease[J].Endocr Pract,2017,23(2):1-87.
[37] Tóth S,Fedacˇ KJ,Pekárová T,et al.Elevated circulating PCSK9 concentrations predict subclinical atherosclerotic changes in low risk obese and non-obese patients[J].Cardiol Ther,2017,6(2):281-289.
[38] Koren MJ,Scott R,Kim JB,et al.Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia(MENDEL):a randomised, double-blind, placebo-controlled, phase 2 study[J].Lancet,2012,380(9858):1995-2006.
[39] Milionis H,Liamis G,Elisaf M.Proprotein convertase subtilisin kexin 9 inhibitors:next Generation in lipid-lowering therapy[J].Expert Opin Biol Ther,2015,15(2):287-298.
[40] Han DF,Ma JH,Zhang XN,et al.Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and uygur populations[J].Medical Science Monitor,2014,20(5):1758-1767.
[41] 崔琴,鞠现霞.PCSK9在高胆固醇血症中的作用研究进展[J].医学综述,2010,16(16):2454-2456.[42] Naureckiene S,Ma L,Sreekumar K,et al.Functional characterization of Narc 1, a novel proteinase related to proteinase K[J].Arch Biochem Biophys,2003,420(1):55-67.
[43] Cai GJ,Zhang BF,Shi GW,et al.The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels:a meta-analysis[J].Lipids Health Dis,2015,14(1):149.
[44] Homer VM,Marais AD,Charlton F,et al.Identification and characterization of two non-secreted PCSK9 mutants associated withfamilial hypercholesterolemia in cohorts from New Zealand and South Africa[J].Atherosclerosis,2008,196(2):659-666.
[45] Dong B,Singh AB,Azhar S,et al.High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels[J].Atherosclerosis,2015,239(2):364-374.
[46] Mcnutt M C, Lagace T A, Horton J D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells[J]. 2007, 282(29):20799-20803.
[47] Roubtsova A,Munkonda MN,Awan ZA,et al.Circulating proprotein convertase subtilisin/kexin 9(PCSK9)regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue[J].Arterioscler Thromb Vasc Biol,2011,31(4):785-U162.
[48] Gu HM,Adijiang A,Mah M,et al.Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding[J].J Lipid Res,2013,54(12):3345-3357.
[49] Li S,Guo YL,Xu RX,et al.Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis[J].Cardiology,2014,129(1):14-15.
[50] 任海艳,王丽宏,车慧.前蛋白转化酶枯草溶菌素 9抑制剂与血脂异常的相关研究[J].中国医师进修杂志,2017,40(5):474-477.
[51] Abboud S, Karhunen PJ, Lutjohann D, et al. Proprotein convertase subtilisin/kexin type 9(PCSK9)gene is a risk factor of large-vessel atherosclerosis stroke[J]. PloS one, 2007,2(10):e1043.
[52] Slimani A,Harira Y,Trabelsi I,et al.Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a tunisian cohort[J].J Mol Neurosci,2014,53(2):150-157.
[53] Tang Z, Jiang L, Peng J, et al.PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappa B activation in THP-1-derived macrophages[J].Int J Mol Med, 2012, 30(4):931-938.
[54] Olsen A,Fosbol EL,Lindhardsen J,et al.Duration of treatment with nonsteroidal Anti-Inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction a nationwide cohort study[J].Circulation,2011,123(20):2226-2235.
[55] Wu CY,Tang ZH,Jiang L,et al.PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway[J].Mol Cell Biochem,2012,359(1/2):347-358.
[56] 王梅,郭彦青,陈萌萌,等.冠心病患者体内前蛋白转化酶枯草溶菌素9水平与炎性因子的相关性分析[J].心肺血管病杂志,2017,36(6):433-435, 450.
[57] Piao MX,Bai JW,Zhang PF,et al.PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways[J].Int J Clin Exp Pathol,2015,8(3):2787-2794.
[58] Chistiakov DA,Bobryshev YV,Nikiforov NG,et al.Macrophage phenotypic plasticity in atherosclerosis:The associated features and the peculiarities of the expression of inflammatory genes[J].Int J Cardiol,2015,184:436-445.
[59] Bingham B,Shen R,Kotnis S,et al.Proapo`ptotic effects of NARC 1(=PCSK9),the gene encoding a novel serine proteinase[J].Cytometry A,2006,69(11):1123-1131.
[60] Rousselet E,Marcinkiewicz J,Kriz J,et al.PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke[J].J Lipid Res,2011,52(7):1383-1391.